Literature DB >> 18367120

High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States.

Janet L Colli1, Christopher L Amling.   

Abstract

OBJECTIVE: Some studies suggest that cholesterol may promote prostate cancer development. High serum cholesterol levels are commonly treated with statins, which have been associated with decreased prostate cancer risks. Statin use has increased in this country during the 1990s while prostate mortality rates have gone down. In this study, we compare high cholesterol levels to prostate cancer mortality rates among states over time periods in which statin use has changed. We hypothesize that prostate cancer risks from high cholesterol may be reduced when statin use is high.
METHODS: State-specific, high cholesterol levels for white males (2001-2003) were compared with age-adjusted prostate cancer mortality rates for each year from 1992 to 2000. To control for medical care access and socioeconomic status, urbanization, family income, and health insurance status were considered.
RESULTS: High cholesterol levels correlate inversely with prostate cancer mortality for: 2000 (R = -0.40, P < 0.01); 1999 (R = -0.37, P < 0.01); and 1998 (R = -0.32, P < 0.05), but there was no significant correlation from 1992 to 1997. Statin use was 46%, 47%, and 49% in 1998, 1999, and 2000, respectively, and ranged from 7% in 1992 to 42% in 1997. Urbanization correlated at the P < 0.05 level from 1994 to 2000 but family income and health insurance status did not correlate.
CONCLUSIONS: High cholesterol levels were associated with lower prostate cancer mortality rates when statin use was high, but not low, suggesting that statins reduce prostate cancer mortality risks.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367120     DOI: 10.1016/j.urolonc.2007.11.029

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

Review 1.  A review of statin use and prostate cancer.

Authors:  Doreen Pon; Andrew Abe; Eric K Gupta
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 2.  Chemoprevention of prostate cancer: what can be recommended to patients?

Authors:  Janet L Colli; Christopher L Amling
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

3.  Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.

Authors:  Emma H Allott; Lauren E Howard; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Stephen J Freedland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-10       Impact factor: 4.254

4.  Preoperative serum lipid profile and outcome in nonmetastatic colorectal cancer.

Authors:  Ting-Ting Hong; Di Shen; Xiao-Ping Chen; Xiao-Hong Wu; Dong Hua
Journal:  Chronic Dis Transl Med       Date:  2016-12-22

5.  SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer.

Authors:  Zhenzhou Xu; Liang Huang; Tao Dai; Xiaming Pei; Longzheng Xia; Gongqian Zeng; Mingji Ye; Kan Liu; Fuhua Zeng; Weiqing Han; Shusuan Jiang
Journal:  Onco Targets Ther       Date:  2021-07-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.